P04.42 Newborn affected by maternal use of hallucinogens

Name of the Condition

• Newborn affected by maternal use of hallucinogens
• ICD Code: P04.42

Summary

This condition describes health effects in a newborn resulting from maternal use of hallucinogens during pregnancy or breastfeeding. The newborn may exhibit signs or symptoms due to exposure to these substances, which can impact neonatal adaptation and health.

Causes

Maternal use of hallucinogens, such as LSD, psilocybin, or other psychedelic substances, can cross the placenta and affect the fetus. Postnatally, substances in breast milk may also cause adverse effects in the newborn. The specific hallucinogens and their timing of exposure influence the newborn's condition.

Risk Factors

• Maternal use of hallucinogens during pregnancy
• Lack of prenatal screening for substance use
• Breastfeeding while using hallucinogens
• Prolonged or high-dose exposure to these agents
• Maternal health conditions related to substance use

Symptoms

Symptoms vary based on the substance and timing of exposure. Common signs include respiratory distress, poor feeding, lethargy, jitteriness, or withdrawal symptoms. Some newborns may exhibit growth restriction, neurodevelopmental issues, or congenital anomalies.

Diagnosis

Diagnosis involves a thorough maternal history review, including substance use details, newborn clinical assessment, and laboratory testing if indicated. Documentation should specify the type of hallucinogen and timing of exposure.

Treatment Options

Treatment focuses on supportive care, such as monitoring vital signs, managing withdrawal symptoms, and addressing feeding difficulties. In severe cases, specialized neonatal care may be required. Long-term follow-up assesses developmental outcomes.

Prognosis and Follow-Up

Prognosis depends on the extent of exposure, timing, and newborn response. Early intervention and monitoring improve outcomes. Follow-up includes tracking growth, neurodevelopment, and addressing any persistent symptoms.

Complications

Potential complications include respiratory distress, feeding difficulties, neurodevelopmental delays, or congenital anomalies. Severe cases may require intensive care or long-term support.

Lifestyle & Prevention

Prevention involves maternal education on substance risks, prenatal screening, and avoiding hallucinogen use during pregnancy or breastfeeding. Supportive resources for substance use disorders can reduce exposure.

When to Seek Professional Help

Seek immediate medical attention if the newborn shows signs of distress, such as difficulty breathing, poor feeding, or abnormal behavior. Maternal substance use should be disclosed to healthcare providers promptly.

Tips for Medical Coders

Document the maternal use of hallucinogens, including timing and substance type, to support coding accuracy. Ensure clinical notes align with the diagnosis and specify any related neonatal symptoms or interventions.